Knight Therapeutics sees a slight decline this week despite positive regulatory news.
Knight Therapeutics Inc. (GUD.TO) has seen a modest drop in its stock price this week, closing down 1.72% on Friday and 3.09% over the past week. However, the company’s year-to-date performance is strong, with a notable increase of 64.64%. The recent approval of TAVALISSE® in Colombia may have sparked some optimism, but it didn’t lead to a rise in the stock this week.
Advertisement
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$972.49M
P/E
66.0x
52W high
$10.17
52W low
$5.66
1W change
-3.09%
Beta
0.04
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 15.0% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$11.19
+15.0% Upside
Current Price
C$9.73
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
34.0%
Annualized
90-Day Vol
33.0%
Annualized
Trend (90d)
+10.9%
Annualized drift
90d Mean
C$10.12
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$9.86 | C$8.77 – C$11.09 |
| 60 trading days | C$9.99 | C$8.46 – C$11.79 |
| 90 trading days | C$10.12 | C$8.26 – C$12.40 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: While the recent regulatory approval is a positive sign for Knight Therapeutics, the stock's performance shows a cautious market response. Investors should monitor how this approval affects future sales and the company’s overall financial health.
Knight Therapeutics Stock Performance: YTD +64.64%
Knight Therapeutics' stock has experienced significant growth this year, but recent trading patterns suggest that investors are cautious given the high valuation.
Bull case
The regulatory approval of TAVALISSE® in Colombia could open new revenue streams for Knight Therapeutics, potentially strengthening its market position and boosting investor confidence.
Bear case
Despite the positive news, the recent downward trend in the stock price indicates that investors may be concerned about the company’s current valuation and profit margins.
Recent Price Action
Advertisement
Knight Therapeutics Inc. closed at C$9.73 on Friday, reflecting a decrease of 1.72% for the day and a 3.09% decline over the past week. However, over the last month, the stock has gained 2.42%, contributing to an impressive year-to-date increase of 64.64%. This performance highlights the stock's volatility, despite its overall upward trend this year.
Company News and Catalysts
This week, Knight Therapeutics announced the regulatory approval of TAVALISSE® in Colombia, which is expected to create new market opportunities for the company. This approval is significant as it could lead to increased revenue streams, although the immediate market reaction has been muted. Investors will be closely watching to see how this approval translates into sales and whether it can improve the company’s financial health moving forward.
Technical Picture
Knight Therapeutics' stock is currently trading just above its 50-day moving average of C$9.71, indicating a slight bullish trend in the short term. The 200-day moving average stands at C$7.66, reflecting a stronger long-term bullish sentiment, as the price is up 26.9% compared to this average. The stock has a beta of 0.04, suggesting lower volatility compared to the overall market. The 52-week trading range for GUD.TO has been between C$5.66 and C$10.17, with the current price sitting at 90% of this range. Recent trading volume has been slightly lower than the 20-day average, with 82,030 shares traded against an average of 83,776 shares.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
